Improving the efficiency of quantitative (1)H NMR: an innovative external standard-internal reference approach.

The classical internal standard quantitative NMR (qNMR) method determines the purity of an analyte by the determination of a solution containing the analyte and a standard. Therefore, the standard must meet the requirements of chemical compatibility and lack of resonance interference with the analyte as well as a known purity. The identification of such a standard can be time consuming and must be repeated for each analyte.

N-N migration of a carbamoyl group in a pyrazole derivative revealed by NMR.

During a synthesis of 5-amino-4-(6-methoxy-2-methylpyridin-3-yl)-3-methyl-1H-pyrazole-1-carboxamide (see Scheme 1), a side-reaction produced 3-amino-4-(6-methoxy-2-methylpyridin-3-yl)-5-methyl-1H-pyrazole-1-carboxamide as a by-product that forms an equilibrium with the target-compound. The structure of the by-product was elucidated by the interpretation of 1D and 2D (HMQC, HMBC) NMR data where (1)H-(15)N HMBC correlations revealed the position of carbamoyl group attachment on the pyrazole. Comparison of structures of the target-compound and the by-product showed that the latter resulted from N-N migration of the carbamoyl group in the target-compound.

Identification and control of a degradation product in Avapro film-coated tablet: low dose formulation.

A degradation product was formed during the long-term stability studies (LTSS) of the low dose formulation of Avapro film-coated tablet. The degradant was identified as the hydroxymethyl derivative (formaldehyde adduct) of the drug substance, irbesartan, based upon analysis with LC/MS, LC/MS/MS, and chromatographic comparison to the synthetic hydroxymethyl degradation product. Laboratory studies demonstrated that the interaction of individual excipients with the drug substance at elevated temperature and polyethylene glycol (PEG) used in the coating material, Opadry II White, leads to the generation of this formaldehyde adduct.

Degradation of a lyophilized formulation of BMS-204352: identification of degradants and role of elastomeric closures.

The purpose of this study was to identify two degradation products formed in the parenteral lyophilized formulation of BMS-204352, investigate the possible role of elastomeric closures in their formation, and develop a strategy to minimize/control their formation. The first degradant was identified as the hydroxymethyl derivative (formaldehyde adduct, BMS-215842) of the drug substance formed by the reaction of BMS-204352 with formaldehyde. Structure confirmation was based on liquid chromatography/mass spectroscopy (LC/MS), nuclear magnetic resonance (NMR), and chromatographic comparison to an authentic sample of the hydroxymethyl degradation product, BMS-215842.

Influence of formaldehyde impurity in polysorbate 80 and PEG-300 on the stability of a parenteral formulation of BMS-204352: identification and control of the degradation product.

The purpose of this study was to identify a degradation product formed in the clinical parenteral formulation of BMS-204352, investigate the role of excipients in its formation, and develop a strategy to minimize/control its formation. The degradant was identified as the hydroxy methyl derivative (formaldehyde adduct, BMS-215842) of the drug substance based upon liquid chromatography/mass spectroscopy (LC/MS), liquid chromatography/mass spectroscopy/mass spectroscopy (LC/MS/MS), nuclear magnetic resonance (NMR), and chromatographic comparison to an authentic sample of hydroxymethyl degradation product, BMS-215842. An assay method for the detection of formaldehyde based on HPLC quantitation of formaldehyde dinitrophenylhydrazone was developed to quantitate its levels in various Polysorbate 80 and PEG 300 excipient lots.